title: Large variations in the use of oral anticoagulants in stroke patients with atrial fibrillation: a Swedish national perspective.
abstract: OBJECTIVE
  To explore nation-wide use of anticoagulation in stroke patients with atrial fibrillation, in routine clinical practice in Sweden.
  
  
  METHODS
  Cross-sectional cohort study.
  
  
  METHODS
  Patients included in Riks-Stroke, the Swedish national quality register for stroke care, during 2001.
  
  
  METHODS
  Hospitals with incomplete coverage were excluded, leaving 4538 stroke patients with atrial fibrillation amongst 18 276 stroke patients from 75 hospitals in six health care regions.
  
  
  METHODS
  Treatment with oral anticoagulants.
  
  
  RESULTS
  At stroke onset, the proportion of patients with atrial fibrillation and first-ever stroke, receiving oral anticoagulants as primary prevention was 11.0% (range 8.4-13.5% between regions and 2.5-24.4% between hospitals). Younger age, male sex and diabetes at stroke onset independently predicted primary prevention with oral anticoagulants. The proportion of stroke patients with atrial fibrillation receiving oral anticoagulants as secondary prevention at discharge was 33.5% (range 29.9-40.6% between regions and 16.4-61.9% between hospitals). Independent predictors for secondary prevention were younger age, male sex and independent activities of daily life (ADL) function before the stroke, being discharged to home, being fully conscious on admission and health care region.
  
  
  CONCLUSIONS
  There were variations between hospitals and regions that differences in age, sex, functional impairments and comorbidities could not fully explain. This indicates that evidence-based primary and secondary prevention of embolic stroke is insufficiently practised. Local factors seem to determine whether patients with atrial fibrillation gain access to optimal prevention of stroke or not.
authors.affiliation: Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. eva.lotta.glader@medicin.umu.se
authors.forename: E-L
authors.initials: EL
authors.lastname: Glader
authors.forename: B
authors.initials: B
authors.lastname: Stegmayr
authors.forename: B
authors.initials: B
authors.lastname: Norrving
authors.forename: A
authors.initials: A
authors.lastname: Terént
authors.forename: K
authors.initials: K
authors.lastname: Hulter-Asberg
authors.forename: P-O
authors.initials: PO
authors.lastname: Wester
authors.forename: K
authors.initials: K
authors.lastname: Asplund
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D001291:Attitude of Health Personnel; D002543:Cerebral Hemorrhage / Q000150:complications; D002544:Cerebral Infarction / Q000150:complications / Q000517:prevention & control; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012008:Recurrence; D012307:Risk Factors; D020521:Stroke / Q000150:complications / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors